Additional risk factors contributing to the development of RT include bulky lymphadenopathy or hepato-splenomegaly, elevated beta-2-microglobulin, low platelet count, advanced disease stage, prior CLL therapy involving a combination of purine analogs and alkylating agents, and a higher number of lines of therapy [76,77]. The gene discussed is B2M; the disease is B-cell chronic lymphocytic leukemia.